Profile
François Lescure is the founder and Chairman of Teladoc Health France SAS, which is founded in 2008.
He is currently the General Manager at Invectys SAS, where he started in 2022 and is still active.
François Lescure active positions
| Companies | Position | Start |
|---|---|---|
Teladoc Health France SAS
 Teladoc Health France SAS Life/Health InsuranceFinance Teladoc Health France SAS operates as a holding company with interests in the provision of healthcare services. It manages an online platform that offers medical consultation. The company was founded by François Lescure, Marc Guillemot and Frédéric Dussauze in 2008 and is headquartered in Longjumeau, France. | Founder | 31/12/2007 |
Invectys SAS
 Invectys SAS Pharmaceuticals: MajorHealth Technology Invectys SAS is a French company that specializes in cancer immunotherapeutics. The private company is based in Paris, France and was founded in 2010 by Pierre Demoyen. The company focuses on blocking immunosuppressive pathways using monoclonal antibodies and cancer to maintain homeostasis in the immune system. The company's goal is to induce the production of cancer-specific antigens in the patient's body through DNA vaccines. François Lescure has been the CEO of the company since 2022. | Chief Executive Officer | 10/04/2022 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Teladoc Health France SAS
Teladoc Health France SAS Life/Health InsuranceFinance Teladoc Health France SAS operates as a holding company with interests in the provision of healthcare services. It manages an online platform that offers medical consultation. The company was founded by François Lescure, Marc Guillemot and Frédéric Dussauze in 2008 and is headquartered in Longjumeau, France. | Finance |
Invectys SAS
Invectys SAS Pharmaceuticals: MajorHealth Technology Invectys SAS is a French company that specializes in cancer immunotherapeutics. The private company is based in Paris, France and was founded in 2010 by Pierre Demoyen. The company focuses on blocking immunosuppressive pathways using monoclonal antibodies and cancer to maintain homeostasis in the immune system. The company's goal is to induce the production of cancer-specific antigens in the patient's body through DNA vaccines. François Lescure has been the CEO of the company since 2022. | Health Technology |
- Stock Market
- Insiders
- François Lescure
